Can multiple myeloma become a curable disease
暂无分享,去创建一个
J. Raemaekers | E. Jaffe | S. Swerdlow | S. Pileri | G. Borm | J. Vardiman | K. Hebeda | M. Mackenzie | H. A. Tromp
[1] J. Besalduch,et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. , 2011, Blood.
[2] M. Baccarani,et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.
[3] B. Barlogie,et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. , 2010, Blood.
[4] B. Barlogie,et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. , 2010, Blood.
[5] J. Bladé,et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. , 2010, Blood.
[6] M. Boccadoro,et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] B. Barlogie,et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Crowley,et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Richardson,et al. How I treat multiple myeloma in younger patients. , 2009, Blood.
[10] A. Órfão,et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. , 2009, Blood.
[11] H. Avet-Loiseau,et al. The role of complete response in multiple myeloma. , 2009, Blood.
[12] B. Barlogie,et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.
[13] R. Hayes,et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.
[14] L. Escoda,et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] K. Anderson,et al. Individualizing treatment of patients with myeloma in the era of novel agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Salvatore,et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma , 2008, Journal of Nuclear Medicine.
[17] B. Barlogie,et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Fanin,et al. A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.
[19] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[20] A. Órfão,et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. , 2002, Blood.
[21] Marcos González,et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. , 2005, Haematologica.